Home > Cardiology > ISTH 2020 > COVID-19 and Thrombosis > Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients

Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients

Presented By
Dr Hanny Al-Samkari, Massachusetts General Hospital, USA
Conference
ISTH 2020
Trial
Cohort study
A cohort study of nearly 3,000 COVID-19 patients in intensive care did not reveal any advantages in preventing death by medicating with anticoagulation at therapeutic dosage. Obesity and high D-dimer levels were among the recognised independent factors associated with VTE. A strong association has been found between coagulation-related complications like venous thromboembolism (VTE) and COVID-19 [1-4]. “As a result, it has been hypothesised that the hypercoagulability in patients with COVID-19 may be a key mechanistic pathway leading to multiple organ failure and death and it has gained considerable attention as a potential therapeutic target,” said Dr Hanny Al-Samkari (Massachusetts General Hospital, USA) [5]. Up to now, no randomised controlled trial data is available to give guidance on the optimal prophylactic dose of anticoagulation for critical patients in ICU. Dr Al-Samkari and his team set up a large 67-centre cohort study conducted in US centres t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on